ArticleCase reports in infectious diseases2026
Relapsing Nasal Septal Leishmaniasis: Lessons in Long-Term Multidisciplinary Management Case Report.
Article in Case reports in infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Relapsing Nasal Septal Leishmaniasis: Lessons in Long-Term Multidisciplinary Management Case Report.Case reports in infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Mucosal leishmaniasis (ML) is a rare, destructive, and recurrent protozoal infection caused by Case Presentation: We present a case of a 48-year-old healthy male from Venezuela with prior CL treated with intravenous meglumine antimoniate who subsequently developed progressive nasal symptoms consistent with ML. Initial therapy with oral fluconazole was ineffective, but treatment with miltefosine led to symptom resolution. The patient underwent four-staged reconstructive surgeries with ENT. Thirty-eight months later, the patient developed recurrent symptoms, and biopsy confirmed infection with Discussion: This case highlights the relapsing nature of ML, its potential for extensive mucosal damage, and the importance of a structured, long-term care plan. This case in particular is unique given the extended delay before recurrence following miltefosine therapy. The high recurrence rate of Conclusion: Early recognition of ML, timely systemic therapy, structured multidisciplinary care, and adherence to a long-term surveillance plan are critical to prevent mucosal destruction and manage relapses effectively. Extended surveillance may be warranted to detect late relapses in patients treated with newer or more effective agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.